Dactolisib
Dactolisib
Dactolisib (pronounced as dak-toh-li-sib), also known as BEZ235, is a dual inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). It is an experimental drug compound that has been studied for its potential use in the treatment of various types of cancer.
Etymology
The name "Dactolisib" is derived from the combination of the words "dactyl", which means 'finger' in Greek, and "lisib", which is an abbreviation for 'inhibitor'. This is in reference to the drug's function as an inhibitor that targets specific proteins in the body.
Mechanism of Action
Dactolisib works by inhibiting the activity of PI3K and mTOR, two proteins that play a crucial role in cell growth and survival. By blocking these proteins, Dactolisib can potentially slow down or stop the growth of cancer cells.
Related Terms
- Phosphoinositide 3-kinase (PI3K): A family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer.
- Mammalian target of rapamycin (mTOR): A type of protein that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, autophagy, and transcription.
- Dual inhibitor: A type of drug that inhibits two or more enzymes or receptors.
- Cancer: A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
External links
- Medical encyclopedia article on Dactolisib
- Wikipedia's article - Dactolisib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski